Fulcrum Therapeutics (FULC) Enterprise Value: 2019-2025
Historic Enterprise Value for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $297.0 million.
- Fulcrum Therapeutics' Enterprise Value rose 97.81% to $297.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$384.7 million, marking a year-over-year decrease of 80.86%. This contributed to the annual value of $12.5 million for FY2024, which is 93.10% down from last year.
- Latest data reveals that Fulcrum Therapeutics reported Enterprise Value of $297.0 million as of Q3 2025, which was up 88.85% from $157.3 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Enterprise Value ranged from a high of $927.8 million in Q1 2022 and a low of -$71.1 million during Q1 2025.
- Moreover, its 3-year median value for Enterprise Value was $169.8 million (2023), whereas its average is $193.2 million.
- In the last 5 years, Fulcrum Therapeutics' Enterprise Value skyrocketed by 547.06% in 2021 and then crashed by 113.06% in 2025.
- Fulcrum Therapeutics' Enterprise Value (Quarterly) stood at $681.9 million in 2021, then slumped by 49.58% to $343.8 million in 2022, then tumbled by 47.34% to $181.1 million in 2023, then plummeted by 93.10% to $12.5 million in 2024, then surged by 97.81% to $297.0 million in 2025.
- Its Enterprise Value stands at $297.0 million for Q3 2025, versus $157.3 million for Q2 2025 and -$71.1 million for Q1 2025.